Questcor Pharmaceuticals — Oppenheimer Healthcare Conference 2013
37 slides from Questcor Pharmaceuticals's conference presentation, Dec 11, 2013

Slide 1: Oppenheimer Healthcare Conference, December 11, 2013
Exhibit 99.1 NASDAQ: Healthcare OPPENHEIMER December Exhibit 99.1 11, Conference QCOR 2013

Slide 2: Safe Harbor Statement
Safe Note: statements include, or disruptions of associated and federal with to business unfavorable volatility K 2The for Acthar estimate effectively manage, patient development risk Harbor U.S. the Except and but factors caused year in to compliance health with relate reserves and or state our are

Slide 3: Questcor: biopharmaceutical company focused on autoimmune and inflammatory disorders
A biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders 3Questcor

Slide 4: Investment Highlights
Investment Flagship have 4Increasing increased product investment Highlights rapidly Actharin has R&D a unique to growtherapeutic the body of role evidence and sustainable and diversify competitive Profitable, advantages strong cash Acthar flowisand approved balanceforsheet; 19 indications, returned

Slide 5: 3-Year Quarterly Net Sales ($M)
3-Year Quarterly $140.3 $112.5 $160.5 $184.6 $46.0 $75.5 $29.3 $31.3 5Q3 ‘10$36.8 $96.0 $59.8 Net $135.1 Q4Net ‘10 Sales Sales Q1 ‘11 ($M) Q2 $236.3 ‘11 Q3 ‘11 Q4 ‘11 Q1 ‘12 Q2 ‘12 Q3 ‘12 Q4 ‘12 Q1 ‘13 Q2 ‘13 Q3 ‘13

Slide 6: Acthar Net Sales ($M) and Business Diversification
Acthar Net ($M) $717 Infantile ~2% $509 7%-12% 30%- 20%- Rheumatology $88 $218 2009 6TTMSales $115 Other Nephrology 2010 Therapeutic 2013: %35% %25% Business Spasms Acthar 2011 Trailing 2012 Diversification Estimated Area twelve TTM (Q3 % months 2013) 2013 Net Continues MS Sales through by September

Slide 7: Expanding Acthar Sales Across Multiple Therapeutic Areas
Expanding Acthar Infantile $717 Multiple $88 $218 Other Rheumatology Nephrology 2009 *Numbers 7The $115 underlying 2010 Net Spasms Sclerosis on 2011 Acthar Sales the allocation 2012 ($M) bar Sales $509 graph TTM Across ofrepresent 2013 Acthar Therapeutic net actual salesActhar Areas is based neton s

Slide 8: Net Income GAAP and Non-GAAP ($M)
Net Income GAAP ($M) $210 $198 CAGR $265 $299 $80 77% $27 2009 8TTM$84 $35 2010 ($M) 2013: Net 79% $292011 Income Trailing Growth $392012Non-GAAP twelve TTM months 2013Net 2009 through Income 2010September 2011 2012 30, TTM 2013; 2013See reconciliation table in Appendix

Slide 9: Diluted EPS GAAP and Non-GAAP
Earnings GAAP CAGR $4.34 $4.89 $1.21 81% $0.40 $1.27 2009 9TTM 2010 2013: $3.14 $0.54 Diluted 83% Growth 2011 Trailing $3.33 $0.44 EPS 2012 $0.60 Non-GAAP twelve TTM months 2013Diluted 2009 through 2010 EPSSeptember 2011 2012 30, TTM 2013; 2013See reconciliation table in Appendix

Slide 10: Q3-2013 Financial Results
Q3-2013 Q3 Net Fully Cash *Diluted 10Includes –Sales 2013 and Flow Diluted, Shares Financial Short ($M) $75 Q3 from GAAP Non-GAAP –million Outstanding Term $236.3 2012 Operations Results Investments EPS Change in $140.3 restricted $1.52 EPS 62.1 ($M) 68% $1.68 $0.91 61.4 $108.9 ($M) cash. $0.97 67%

Slide 11: Recent Updates: Dividend, Buyback, Board Committees
Recent $0.30 500K Board -–Advisory Forecast Q4-11 Total as Q4-12 Q3-12 12/5 Q1-13 11 500 To Will Record Distribution Paid assist 1,000 shares Dividend level also Acthar Rxs Updates ofQ1-12 date: Committees Q2-12 in assess Q2-13 1,500 Science repurchased ongoing date: 1/17/14 declared and potential 2

Slide 12: Acthar Flagship Product Overview and Strategy
Acthar Flagship 19 Key Nephrotic Significant Expand Strategy: Develop *In with 12 approved this Therapeutic such Overview presentation, awareness, Rheumatology Product: conditions. Syndrome, areas indications Areas: of appropriate unmet the Investors Multiple and terms need; other Sclerosis “Nephrot

Slide 13: Nephrotic Syndrome (NS)
Nephrotic Characterized (nephrotic-range Caused (egeg,, Can Significant iMN,, Sub-Nephrotic ~35K~35,000 13 result FSGS, iMN,, by Syndrome in aunmet number end-stage IgA, FSGS, by NS Nephrotic proteinuria) excessive Patients need; LN, of IgAMPGN, renal underlying few nephropathy, ~90,000 (US) spillin

Slide 14: Multiple Sclerosis (MS)
Multiple MS Estimated Loss Relapses Treated Adequately ~30K~100,000 14 isofa ability sensation vision Relapses neurodegenerative Sclerosis range can >100,000 have to Annual from Addressable walk in(MS) a the measurable relapses/year mild Relapses extremities Relapse todisease severe ~70K and (US) oc

Slide 15: Infantile Spasms (IS)
Infantile Devastating, Can Acthar ~780 cause Pts~1,500 isSpasms Penetration often permanent ultra-rare considered Patients (IS) developmental form (US) the of15 “gold childhood standard” disabilities, epilepsy andincreased is currently mortality used to treat ~50% of IS patients

Slide 16: Acthar's Rheumatology Opportunity
Acthar’s Rheumatology Rheumatology-related Acthar –cases Each adequately Some additional Positive Force *See Approximately DM/PM PsA 16Ankylosing Dermatomyositis/Polymyositis Systemic Rheumatoid Psoriatic AShttp://www.acthar.com/files/Acthar-PI.pdf can low-dose from cases label* Lupus initial RA Lar

Slide 17: Initiating a Pulmonology Pilot Commercialization Effort for Sarcoidosis
Initiating Acthar A Cause May Asymptomatic ~130K 17systemic beisis ~20,000 asymptomatic unknown approved a Pilot inflammatory Potential Patients Commercialization for or the or (US) chronic disease treatment Adequately and where Effort ofmay Acthar respiratory cellcause innodules Pulmonology Patient

Slide 18: Mostly Large Markets with Growth Potential
Mostly Large Growth Potential Infantile PM/DM Nephrotic 18 Potential 20,000 Spasms Acthar Syndrome Addressable 2% Patient 1,500 (U.S. Rheumatoid 35,000 52% Only) % Acthar Markets Multiple 9% Sarcoidosis Arthritis Penetration with Sclerosis 80,000 20,000 Indication Flares 0.5% 0.2% 30,000 Lupus Popul

Slide 19: Synacthen Depot Rights Acquisition Opportunity
Synacthen Acquired Depot Rights Opportunity Expands Provides Further *Subject 19 in todiversifies presence U.S. to foundation develop license (tetracosactide certain to reinvigorate toand in business closing develop for inflammatory commercialize next tetracosactide)) conditions Synacthen and genera

Slide 20: Advancing Understanding of Melanocortin Peptides
Advancing One Believed –Questcor 20 Acthar MC1R, Differences of 9 (porcine families to currently MC2R, Our modulate inUnderstanding chemical ACTH MC3R, ofhas hormones the two 1-39); immune MC4R, structure distinct produced of Synacthen Acthar and system melanocortin-peptide influence MC5R by and and

Slide 21: Acthar Mechanism of Action: Clinical and Preclinical Observations
Acthar –Clinical Preclinical 1: 2: 21Acthar Bomback GongMechanism observations et hasal, observations et been Kidney al, Am shown successfully of International, Action J Nephrol demonstrate to have used 2012;36:58–67 increased 83, tosteroid-independent induce January efficacy remission 2013vs. corti

Slide 22: Implications for Acthar and Other Melanocortins
Implications –WeWe Dozens 22Immune Inflammatory Some Homeostasis now of cellmoderate-to-severe system believe function of Acthar process Acthar and and Other medical other Melanocortins melanocortin conditions(Synacthen may peptides benefit impact and from newActhar MCs) or other melanocortin peptid

Slide 23: Significantly Increasing Investment in R&D
Significantly Have –Investigating R&D $11 $17 $34 $52 2008 23Company Independent Direct Immunomodulation $10 2009 funded Investment $11 effect 2010 sponsored or Increasing potential physician on have 2011 ($M) biochemical approved and 2012 pre-clinical biological Investment sponsored anti-inflammato

Slide 24: Expanding the Body of Evidence for On-Label and New Indications
Expanding Pre-Clinical IDIOPATHIC AMYOTROPHIC ACUTE 24 syndrome RESPIRATORY the Phase MEMBRANOUS BodyLATERAL 1 Phase of Evidence DISTRESS 2 Phase SCLEROSIS NEPHROPATHY for3 On-Label Phase 4 and SYSTEMIC New Indications/Targets LUPUS ERYTHEMATOSUS DIABETIC NEPHROPATHY

Slide 25: ALS Phase 2 Open-Label Study
ALS Goals –Study Findings 25 Assess Inform Enroll 8-week Patients Phase Design up short-term to dosage treatment, randomized 2to Drive Open-Label 40selection patients Design safety plus to optional one at for Safety for and multiple Pivotal of future tolerability four Study 28-week studies dosing Ef

Slide 26: ARDS Phase 2 Study
ARDS Goals –Study Findings 26 Assess Determine Inform 4-week Enroll Patients Design Phase up if to dosage randomized, randomized Acthar to Drive if2210 Acthar Safety selection Design reduces patients increases and to placebo one for for mortality, Efficacy at Pivotal of up future controlled number s

Slide 27: Committed to Creating Long Term Value for Shareholders
Committed Continued Demonstrated Long Highly (projected) –Have Quarterly *Data 2722.7million 5.8 returned term as million selective, ofdividend stewardship investment to 12/11/13 shares Creating ability shares $441 strategic increased remain million repurchased toinof Long execute R&D Acthar diversi

Slide 28: Increasing Penetration and Developing New Growth Opportunities
Increasing –Untapped Developing Strong 28NS and Rheumatology Pilot Possible Developing selling Platform free MS international Acthar penetration cash new international market effort for flow indications isrole aGrowth beginning new penetration generation in of market dermatology current Acthar marke

Slide 29: NASDAQ: QCOR, December 2013
NASDAQ:2013 December 29 QCOR

Slide 30: Reconciliation: Three and Nine Months Ended September 30, 2013
Reconciliation Three September 2013 Share-based Depreciation Interest Compensation Foreign BioVectra Impairment Consolidated Medicaid Adjusted Notes Net Use Our 1. 2. 3. 4. R&D 5. 6. 7. 8. 9. 30 Share-based Depreciation Interest Compensation Foreign Medicaid BioVectra Impairment sales sales—BioVectr

Slide 31: Reconciliation: Net Income and EPS 2009 to TTM 2013
Reconciliation 2009 Tax Stock-based Depreciation Other Medicaid Ohio Impairment GAAP Adjusted 31 adjustments 2010 CAT non-cash Net Net adjustment — 2011 Income of Compensation &Income Income—per (0.01) goodwill of expense Amortization 2012 0Non-GAAP (916) $26,629 per 0.03 for $29,242 per TTM Share—B

Slide 32: Strong Platform for Growth: H.P. Acthar Gel Indications
Strong 1.1 1.2 H.P. the As require 1.4 During 1.3 (to –.1Psoriatic 32 (polymyositis). .4 As During tide adjunctive resolution Infantile Multiple Rheumatic Collagen Acthar adjunctive platform low-dose an the arthritis; anexacerbation patient Gel exacerbation Spasms: Sclerosis: Diseases: of therapy Di

Slide 33: How Acthar Treats Disease: Mechanism of Action
How Treats By Triggers Properties –Acthar 1Arnason Child 33 ACTH Binds binding Does Neuro autoimmune/inflammatory components to the iset extend melanocortin cells Acthar believed toproduction al. 2011; melanocortin Mult inbeyond Work? many 7Manna have toSclerosis be of receptors types yet steroidoge

Slide 34: Melanocortin Peptides Activate Up to Five Known Receptors
Melanocortin Adrenal MC2R Steroid-dependent Corticosteroids Immune MC5R MC4R MC3R MC1R Effects Direct 34 effect on cortical cells, immune on Peptides CNS organ-specific cells anti-inflammatory cells cells, May Altered kidney Activate cells tissue/organ cells, (eg, Up effects muscle CNS, to Five (ind

Slide 35: Melanocortin Receptors: Tissues and Effects
MCR Macrophages, MC1R Keratinocytes Chondrocytes Respiratory GI MC2R MC3R Podocytes Renal MC4R Endothelial Central •MC5R Lymphocytes 35 Immunomodulation Lipid tract issue/CellTissue/Cell Mesangial Adrenal Melanocytes •Macrophages Exocrine regulation Nervous Cerebral • Cells tract Regulation •Monocyt

Slide 36: New Paid Acthar Prescriptions by Therapeutic Area
New Paid Q3 NS MS IS Rheumatology *Total ** 36Includes 225 Total –370 1,370 Rx Paid 2013 2,450—2,500** ——Comparison number Acthar 230 —prescriptions Q3 3801,400 33% –450 7% 2012 of Prescriptions 7% — prescriptions 4% 7%Q2 30% 460 8% covered –N/M 10% 2013 by 43% by includes Therapeutic commercial all

Slide 37: Biosimilar Complexity: Acthar Formulation and Future Pathways
Biosimilar Complex Formulation –Future 37Possibly Slow Complex Clinical Multi-year synthetic release formulation trial(s) multiple Pathways and and pathway; gel not versions manufacturing and formulation well active athways other and challenging characterized of pharmacology, peptides development AC
Source: SEC EDGAR · 8-K filed Dec 11, 2013
More decks from Questcor Pharmaceuticals Inc
FY2013 Earnings Presentation19 slides · Mar 3, 2014
J.P. Morgan Healthcare Conference 201444 slides · Jan 13, 2014
Q3 2013 Earnings Presentation17 slides · Nov 4, 2013
Q2 2013 Earnings Presentation14 slides · Aug 6, 2013
Investor Presentation (August 2013)29 slides · Aug 6, 2013
Bank of America Merrill Lynch Healthcare Conference 201325 slides · May 14, 2013